Targeting fibroblast growth factor pathways in endometrial cancer

Boris Winterhoff, Gottfried E. Konecny

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


Novel treatments that improve outcomes for patients with recurrent or metastatic endometrial cancer (EC) remain an unmet need. Aberrant signaling by fibroblast growth factors (FGFs) and FGF receptors (FGFRs) has been implicated in several human cancers. Activating mutations in FGFR2 have been found in up to 16% of ECs, suggesting an opportunity for targeted therapy. This review summarizes the role of the FGF pathway in angiogenesis and EC, and provides an overview of FGFR-targeted therapies under clinical development for the treatment of EC.

Original languageEnglish (US)
Pages (from-to)37-47
Number of pages11
JournalCurrent Problems in Cancer
Issue number1
StatePublished - Jan 1 2017

Bibliographical note

Publisher Copyright:
© 2017 The Authors


  • Angiogenesis
  • Endometrial cancer
  • Fibroblast growth factor


Dive into the research topics of 'Targeting fibroblast growth factor pathways in endometrial cancer'. Together they form a unique fingerprint.

Cite this